1. . Crowe SM, Carlin JB, Stewart KI, et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991; 4:770-6.
  2. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483-97.
  3. Tumbarello M, Tacconelli E, de Donati KG, et al. Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies. Eur J Clin Microbiol Infect Dis 2001; 20:498-501.
  4. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992; 6:1293-7.
  5. Cabie A, Abel S, Brebion A, et al. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 1998; 17:812-13.
  6. Dworkin MS, Fratkin MD. Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS. Arch Intern Med 1998; 158:1828.
  7. Murray R, Mallal S, Heath C, et al. Cerebral Mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated Mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001; 20:199-201.
  8. Nalaboff KM, Rozenshtein A, Kaplan MH. Imaging of Mycobacterium avium-intracellulare infection in AIDS patients on highly active antiretroviral therapy: reversal syndrome. Am J Roentgenol 2000; 175:387-90.
  9. Phillips P, Kwiatkowski MB, Copland M, et al. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr 1999; 20:122-8.
  10. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect 2007; 55:464-9.
  11. Riddell J 4th, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med 2007; 5:50.
  12. Desimone JA Jr, Babinchak TJ, Kaulback KR, et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. AIDS Patient Care STDs 2003; 17:617-22.
  13. Lazaro E, Coureau G, Guedj J, et al; ANRS Co3 Aquitaine Cohort. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther 2006; 11:343-50.
  14. Chin DP, Hopewell PC, Yajko DM, et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169:289-95.
  15. MacGregor RR, Hafner R, Wu JW, et al. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res Hum Retroviruses 2005; 21:689-95.
  16. Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234-43.
  17. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 2004; 4:557-65.
  18. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose- ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905-11.
  19. Gardner EM, Burman WJ, DeGroote MA, et al. Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients. Clin Infect Dis 2005; 41:1041-4.
  20. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4e
  21. Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team [erratum in: J Infect Dis 2003; 187:1346.
  22. Hoy JF, Marriott D, Gottlieb T. Managing HIV 5.15 HIV and non- tuberculous mycobacterial infection. Med J Aust 1996; 164:543-5.
  23. Horsburgh CR Jr, Metchock B, Gordon SM,et al. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 1994; 170:573-.
  24. Horsburgh CR Jr, Gettings J, Alexander LN, et al. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985- 2000. Clin Infect Dis 2001; 33:1938-43.
  25. Oldfield EC 3rd, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo- controlled multicenter trial. Clin Infect Dis 1998; 26:611-19.
  26. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392-8.
  27. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-91.
  28. Uthman MM, Uthman OA, Yahaya I. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV. Cochrane Database Syst Rev 2013; 4:CD007191.
  29. Lange CG, Woolley IJ, Brodt RH. Disseminated Mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? Drugs 2004; 64:679-92.
  30. Chene G, Phillips A, Costagliola D, et al. Cohort profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Int J Epidemiol. 2017; 46:797-797.
  31. Jung Y, Song KH, Choe PG, et al. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis. Int J STD AIDS. 2017; 28:1426-1432.
  32. Brooks JT, Song R, Hanson DL, et al; Adult and Adolescent Spectrum of Disease Working Group. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002. Clin Infect Dis 2005; 41:549-53.
  33. Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133:493-503.
  34. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085-92.
  35. Wetzstein NHügel CWichelhaus TA et al. Species distribution and clinical features of infection and colonisation with non-tuberculousmycobacteria in a tertiary care centre, central Germany, 2006-2016. Infection.2019; 47:817-825.
  36. Liu L, Zhang R, Tang Y et al. The importance of non-tuberculous mycobacteria identification in Chinese patients infected with HIV. Biosci Trends. 2018; 12:515-516.
  37. Lan RYang CLan LOu J et al. Mycobacterium tuberculosis and non-tuberculousmycobacteria isolates from HIV-infected patients in Guangxi, China. Int J Tuberc Lung Dis.2011; 15:1669-75.
  38. Shafer RWSierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis.1992; 15:161-2.
  39. Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997; 24:1233.
  40. Foudraine NAHovenkamp ENotermans DW et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS.1999; 13:177-84.
  41. Bell HC, Heath CH, French MA. Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy. AIDS. 2005; 19:2047-9.
  42. Leone S, Giglio S, Maio P, Capasso P et al, Mycobacterium xenopi pulmonary infection resulting in self-limited immune reconstitution inflammatory syndrome in an HIV-1 infected patient. New Microbiol. 2009; 32:415-7.
  43. Kapoor V, Latif A, Warraich FH, Majeed A. First case of acute granulomatous interstitial nephritis with immune reconstitution inflammatory syndrome in a patient with  HIV coinfected with disseminated Mycobacterium kansasii. BMJ Case Rep. 2018; 2018. pii: bcr-2017-222149.